No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Therapy Areas
Drug Classes
Therapy Areas
All Sessions
Resectable NSCLC
Advanced NSCLC
SCLC
Biomarkers
Drug Classes
Targeted Therapies
Immunotherapies
ADCs
All
FEATURED
ILCS
Webinars
Articles
Industry Sponsored
Featured Sessions
Expert Insights
Webinars
The Reading Room
Articles & Research
Oct
02
2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies
High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC
B. Ricciuti
Sep
15
2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC
WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening
Aug
25
2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies
Cleared ctDNA within weeks predicted longer survival on immunotherapy in a 109-patient study
P. Forde
Aug
23
2026
RESEARCH
BiomarkersSCLC
SLFN11 expression across lung neuroendocrine neoplasms: highest in SCLC, and prognostic only there
A. Dingemans
Aug
21
2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies
A ctDNA tumour fraction of 5% or more marks who benefits from adding chemotherapy to checkpoint blockade
D. Planchard
Aug
19
2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies
AIOT expert panel endorses chemo-immunotherapy as a new standard in resectable stage II-III NSCLC
T. CasconeP. FordeA. Passaro
Aug
13
2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies
Pre-surgical ctDNA clearance reached 66% with neoadjuvant nivolumab against 38% with placebo in CheckMate 77T
T. Cascone
Aug
08
2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies
EGFR amplification at baseline marks shorter time on first-line osimertinib, in exon 19 deletions but not L858R
B. Ricciuti
Aug
07
2026
RESEARCH
Advanced NSCLCBiomarkersADCs
EVOKE-01 biomarker analysis: Trop-2 staining did not pick out who does better on sacituzumab govitecan than docetaxel
G. Mountzios
Industry Sponsored
Featured Sessions
Expert Insights
Webinars
The Reading Room
Articles & Research
Oct
02
2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies
High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC
B. Ricciuti
Sep
15
2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC
WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening
Aug
25
2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies
Cleared ctDNA within weeks predicted longer survival on immunotherapy in a 109-patient study
P. Forde
Aug
23
2026
RESEARCH
BiomarkersSCLC
SLFN11 expression across lung neuroendocrine neoplasms: highest in SCLC, and prognostic only there
A. Dingemans
Aug
21
2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies
A ctDNA tumour fraction of 5% or more marks who benefits from adding chemotherapy to checkpoint blockade
D. Planchard
Aug
19
2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies
AIOT expert panel endorses chemo-immunotherapy as a new standard in resectable stage II-III NSCLC
T. CasconeP. FordeA. Passaro
Aug
13
2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies
Pre-surgical ctDNA clearance reached 66% with neoadjuvant nivolumab against 38% with placebo in CheckMate 77T
T. Cascone
Aug
08
2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies
EGFR amplification at baseline marks shorter time on first-line osimertinib, in exon 19 deletions but not L858R
B. Ricciuti
Aug
07
2026
RESEARCH
Advanced NSCLCBiomarkersADCs
EVOKE-01 biomarker analysis: Trop-2 staining did not pick out who does better on sacituzumab govitecan than docetaxel
G. Mountzios